^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | fexagratinib (ABSK091) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer
Excerpt:
...- Provision of either an archival tumour sample or a fresh tumour sample for confirmation of FGFR2 polysomy/gene amplification...
Trial ID:
Source:
Title:
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
Excerpt:
This is a phase II Simon 2 stage design for patients (pts) with FGFR1 (HER2 negative breast/NSCLC) or FGFR2 (gastroesophageal) amplified tumors treated with AZD4547 80mg twice daily...Confirmed RR was 33% (3/9) in FGFR2 amplified GC, and 12.5% (1/8) FGFR1 amplified BC...
DOI:
10.1200/jco.2015.33.15_suppl.2508
Trial ID:
Source:
Title:
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Excerpt:
Eight patients with FGFR1-amplified breast cancer and 9 with FGFR2-amplified gastroesophageal cancer were treated with AZD4547 in a translational clinical trial (Supplementary Fig. S1A). One FGFR1-amplified (12.5% response rate) and 3 FGFR2-amplified (33% response rate) patients had confirmed responses to AZD4547 (Fig. 1A and B), reaching the predefined criteria for efficacy in the FGFR2-amplified cohort.
DOI:
10.1158/2159-8290.CD-15-1246
